SCHEMBL2306567

SCHEMBL2306567

CC(=O)c1ccccc1Sc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.54
CHRM1 P11229 1/20 0.54
CHRM3 P20309 1/20 0.54
ALDH1A1 P00352 5/20 0.50
LMNA P02545 3/20 0.50
BLM P54132 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NOD2 Q9HC29 1/20 0.50
SIRT1 Q96EB6 1/20 0.50
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
SLC6A4 P31645 1/20 0.47
SLC6A9 P48067 1/20 0.47
HPGD P15428 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
S100A4 P26447 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2417850 0.85 SIRT1 (0.67) ALDH1A1LMNABLMSIRT1SLC6A9
SCHEMBL6781026 0.84 NPC1 (0.56) CHRM2CHRM1CHRM3ALDH1A1LMNA
SCHEMBL20591207 0.84 SIRT1 (0.51) ALDH1A1LMNANPSR1SIRT1SLC6A9
SCHEMBL6766212 0.83 CHRM2 (0.49) CHRM2CHRM1CHRM3ALDH1A1LMNA
SCHEMBL6766210 0.83 CHRM2 (0.49) CHRM2CHRM1CHRM3ALDH1A1LMNA
SCHEMBL12504708 0.83 SIRT1 (0.50) CHRM2CHRM1CHRM3ALDH1A1LMNA
SCHEMBL599930 0.83 SIRT1 (0.50) CHRM2CHRM1CHRM3ALDH1A1LMNA
SCHEMBL26842232 0.83 SIRT1 (0.50) ALDH1A1LMNASIRT1SLC6A9HPGD
SCHEMBL11334883 0.83 SIRT1 (0.74) CHRM2CHRM1CHRM3ALDH1A1LMNA
SCHEMBL10396749 0.83 HPGD (0.48) CHRM2CHRM1CHRM3ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381133-A1 TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE HAMAD BIN KHALIFA UNIVERSITY (QA) 2023-11-30 US disclosed
EP-2349999-A1 ALLOSTERIC PROTEIN KINASE MODULATORS Universität des Saarlandes (DE) 2011-08-03 EP disclosed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 WO disclosed
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-09-30 US disclosed
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-06-24 US disclosed
CN-1019388-B Process for preparing N-alkylsulfonamide derivatives FUJISAWA PHARMACEUTICAL CO (JP) 1992-12-09 CN disclosed
CN-88103277-A Novel N-alkane sulfonyl aniline derivatives and preparation method thereof and the pharmaceutical composition that comprises this material 1988-12-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 CHRM2 624/4885CHRM1 274/4885CHRM3 843/4885
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 CHRM2 624/4885CHRM1 274/4885CHRM3 843/4885
US-20230381133-A1 TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE MAPT, TTR, HTT CHRM2 4342/4885CHRM1 4658/4885CHRM3 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.